| Author |
Title |
JournalName |
Year D |
| Click on Column Headers to Re-Sort The Current List |
| Barbeau A, Singh P, Gaudr... |
Effect of 3,4-dimethoxyphenylethylamine injections on the concentratio... |
Rev Can Biol |
1965 |
| Barbeau A, Lescop J, Dupl... |
Effect of 3,4-dimethoxyphenylethylamine injections upon dopamine metab... |
Experientia |
1967 |
| Dalmaz Y, Peyrin L |
SPECIFIC ION-EXCHANGE CHROMATOGRAPKY AND FLUORIMETRIC ASSAY FOR URINAR... |
Journal of Chromatog... |
1976 |
| Quock RM, Beal GA, Chant ... |
Quipazine: a serotoninergic hyperthermic agent in the rabbit |
J.Pharm.Pharmacol. |
1976 |
| Shaffer H |
Methadone and Pregnancy: Perspectives and Prescriptions |
J Psychedelic Drugs |
1979 |
| Buchanan JF, Brown CR |
'Designer drugs'. A problem in clinical toxicology |
Med Toxicol Adverse ... |
1988 |
| Hussain, G. and Manyam, B... |
Mucuna pruriens Proves More Effective than L-DOPA in Parkinson's Disea... |
Phytotherapy Researc... |
1997 |
| Robertson P, DeCory HH, M... |
In vitro inhibition and induction of human hepatic cytochrome P450 enz... |
Drug Metab Dispos |
2000 |
| Schmidt WJ, Mayerhofer A,... |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? |
Neurosci Lett |
2002 |
| Brotchie JM |
CB1 cannabinoid receptor signalling in Parkinson's disease |
Curr Opin Pharmacol |
2003 |
| Kish SJ |
What Is the Evidence That Ecstasy (MDMA) Can Cause Parkinson’s Disease... |
Movement Disorders |
2003 |
| Sotnikova TD, Beaulieu JM... |
Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acut... |
PLoS Biol |
2005 |
| Johnston TH, Millar Z, Hu... |
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxi... |
FASEB J |
2012 |
| Borah A, Paul R, Mazumder... |
Contribution of β-phenethylamine, a component of chocolate and wi... |
Neurosci Bull |
2013 |
| Pinterova N, Horsley RR, ... |
Synthetic Aminoindanes: A Summary of Existing Knowledge |
Front Psychiatry |
2017 |
